# Phase 1/2 Leukemia, Lymphocytic: 26 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials in phase 1/2 for Leukemia, Lymphocytic, Chronic, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Leukemia, Lymphocytic, Chronic, B-Cell trials: 26 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/leukemia-lymphocytic-chronic-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 26
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 29, 2026 | NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | Dana-Farber Cancer Institute | Phase 1/2 | Not yet recruiting | Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847957) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| April 9, 2026 | NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1/2 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520006) |
| July 6, 2025 | NCT07052695 | Mosunetuzumab for CLL MRD Clearance | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052695) |
| May 18, 2025 | NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | MingSight Pharmaceuticals, Inc | Phase 1/2 | Not yet recruiting | CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979076) |
| January 7, 2025 | NCT06762431 | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and... | Vitebsk Regional Clinical Cancer Centre | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06762431) |
| November 20, 2024 | NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | BeOne Medicines | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06697184) |
| October 16, 2024 | NCT06644183 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer, Refractory Leukemia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06644183) |
| August 21, 2024 | NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | AstraZeneca | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell... | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06564038) |
| August 7, 2024 | NCT06542250 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell... | AstraZeneca | Phase 1/2 | Recruiting | B-cell Malignancies | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06542250) |
| August 1, 2024 | NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533579) |
| July 17, 2024 | NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | Vector Vitale LLC | Phase 1/2 | Recruiting | CLL, Solid Tumor, Adult | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06506643) |
| April 15, 2024 | NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364423) |
| June 18, 2023 | NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | IDP Discovery Pharma S.L. | Phase 1/2 | Recruiting | Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05908409) |
| January 27, 2023 | NCT05702853 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Medical University of South Carolina | Phase 1/2 | Recruiting | B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05702853) |
| December 9, 2022 | NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | CRISPR Therapeutics AG | Phase 1/2 | Recruiting | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05643742) |
| March 24, 2022 | NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | BeOne Medicines | Phase 1/2 | Recruiting | B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma... | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05294731) |
| August 16, 2021 | NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | BeOne Medicines | Phase 1/2 | Recruiting | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia... | 689 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05006716) |
| February 25, 2021 | NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04771507) |
| October 19, 2020 | NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly... | Sellas Life Sciences Group | Phase 1/2 | Recruiting | Hematologic Malignancies | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04588922) |
| August 6, 2020 | NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Kartos Therapeutics, Inc. | Phase 1/2 | Recruiting | Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04502394) |
| July 31, 2020 | NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | Ascentage Pharma Group Inc. | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04494503) |
| April 1, 2020 | NCT04329728 | The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | AVM Biotechnology Inc | Phase 1/2 | Recruiting | Lymphoid Malignancies | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04329728) |
| December 4, 2019 | NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | Medical College of Wisconsin | Phase 1/2 | Recruiting | Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04186520) |
| December 5, 2018 | NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | Ottawa Hospital Research Institute | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03765177) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| MingSight Pharmaceuticals, Inc | 1 |
| Vironexis Biotherapeutics Inc. | 1 |
| CRISPR Therapeutics AG | 1 |
| University Hospital Heidelberg | 1 |
| Vitebsk Regional Clinical Cancer Centre | 1 |
| Kartos Therapeutics, Inc. | 1 |
| Ottawa Hospital Research Institute | 1 |
| Nurix Therapeutics, Inc. | 1 |
| AVM Biotechnology Inc | 1 |
| Dana-Farber Cancer Institute | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Medical University of South Carolina | 1 |
| Sellas Life Sciences Group | 1 |
| National Cancer Institute (NCI) | 1 |
| Vector Vitale LLC | 1 |
| Medical College of Wisconsin | 1 |
| IDP Discovery Pharma S.L. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 8 |
| Australia | 6 |
| France | 5 |
| Germany | 4 |
| Italy | 4 |
| Spain | 4 |
| United Kingdom | 4 |
| Japan | 3 |
| South Korea | 3 |
| Canada | 3 |
| Czechia | 2 |
| Denmark | 2 |
| Brazil | 2 |
| Sweden | 2 |
| Belarus | 1 |
| Taiwan | 1 |
| Belgium | 1 |
| Poland | 1 |
| Portugal | 1 |
| Switzerland | 1 |
| Georgia | 1 |
| Moldova | 1 |
| Turkey (Türkiye) | 1 |
| Norway | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
- [Credit unions in the United States](https://specstream.ai/data/businesses/credit-unions/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Appliance manufacturers in the United States](https://specstream.ai/data/businesses/appliance-manufacturers/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
